Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have received a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $7.40.

ATNM has been the subject of a number of analyst reports. Stephens restated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, March 11th.

Actinium Pharmaceuticals Trading Up 5.7 %

NYSE:ATNM opened at $1.30 on Tuesday. The stock has a 50 day moving average of $1.21 and a two-hundred day moving average of $1.47. The firm has a market cap of $40.55 million, a P/E ratio of -0.94 and a beta of 0.10. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Actinium Pharmaceuticals by 3.0% in the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares during the period. Northern Trust Corp grew its stake in Actinium Pharmaceuticals by 4.9% in the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after acquiring an additional 11,812 shares during the period. Los Angeles Capital Management LLC grew its stake in shares of Actinium Pharmaceuticals by 25.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after buying an additional 42,770 shares during the period. Renaissance Technologies LLC grew its stake in shares of Actinium Pharmaceuticals by 49.9% during the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after buying an additional 63,400 shares during the period. Finally, Squarepoint Ops LLC grew its stake in shares of Actinium Pharmaceuticals by 25.4% during the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after buying an additional 37,159 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).